Papapetropoulos Spyridon
- SEC CIK
- 0001832694
No open-market purchases or sales filed in the past year.
Current role at each company
- NEUP Neuphoria Therapeutics Inc.President and CEOas of Sep 2, 2025
- LPCN Lipocine Inc.Directoras of Jun 5, 2025
- VIGL Vigil Neuroscience, Inc.Chief Medical Officeras of Nov 22, 2022
- ADMS Adamas Pharmaceuticals IncDirectoras of Nov 24, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Papapetropoulos Spyridon as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
LPCN Lipocine Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 28, 2022 (view filing)4:33 PM ET | Nov 22 | 6 daysLate | Papapetropoulos SpyridonDirector | PPurchase | +21.7K | $0.47 | +$10.2K | New position21.7K after |
VIGL Vigil Neuroscience, Inc.
Chief Medical Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 22, 2022 (view filing) | Nov 18 | 4 days | Papapetropoulos SpyridonChief Medical Officer | SSale | −300 | $14.00 | −$4.20K | −7.0%4.00K after | |
| May 4, 2022 (view filing) | May 3 | 1 day | Papapetropoulos SpyridonChief Medical Officer | PPurchase | +4.00K | $3.40 | +$13.6K | New position4.00K after |